Makers Laboratories Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

Quality Assessment: Weak Long-Term Fundamentals

Makers Laboratories’ quality rating remains subdued due to its weak long-term fundamental strength. Over the past five years, the company has experienced a negative compound annual growth rate (CAGR) of -15.78% in operating profits, signalling persistent challenges in expanding its core earnings. This decline contrasts sharply with the broader Pharmaceuticals & Biotechnology sector, which has generally exhibited more stable growth trajectories.

Return on Equity (ROE), a key measure of profitability relative to shareholder funds, has averaged a mere 2.20%, indicating low efficiency in generating returns for investors. The latest data shows an ROE close to zero, underscoring the company’s struggle to convert equity into meaningful profits. This weak profitability profile weighs heavily on the company’s quality grade and investor confidence.

Valuation: Elevated Price to Book Ratio Amid Profit Declines

Despite the weak profitability, Makers Laboratories trades at a premium valuation with a Price to Book (P/B) ratio of 1.1. This valuation is considered very expensive relative to its peers, especially given the company’s deteriorating profit performance. Over the last year, the stock’s profits have plunged by 82.7%, a stark contrast to its premium market pricing.

The stock’s current price of ₹136.00 is closer to its 52-week low of ₹109.00 than its high of ₹173.70, reflecting volatility but also a lack of sustained upward momentum. The premium valuation amid declining earnings raises questions about the stock’s risk-reward profile and justifies the downgrade in its valuation grade.

Financial Trend: Mixed Quarterly Performance but Negative Long-Term Returns

On a quarterly basis, Makers Laboratories reported positive results for Q3 FY25-26, with net sales reaching a record ₹35.67 crores and PBDIT at ₹4.16 crores. The operating profit margin to net sales also improved to 11.66%, indicating some operational efficiencies in the short term.

However, these quarterly gains have not translated into sustained financial momentum. The stock’s year-to-date return stands at a positive 15.11%, outperforming the Sensex’s negative 2.08% return over the same period. Yet, over the last one year, the stock has underperformed significantly, delivering a negative return of -8.08% compared to the BSE500’s 13.53% gain. Over five years, the stock’s return is a dismal -50.88%, while the Sensex has surged 61.40%.

Technical Analysis: Shift to Mildly Bearish Outlook

The most significant trigger for the downgrade is the change in Makers Laboratories’ technical grade, which shifted from sideways to mildly bearish. Key technical indicators present a mixed but predominantly negative picture:

• MACD: Weekly readings remain mildly bullish, but the monthly MACD is bearish, indicating weakening momentum over the longer term.
• RSI: Both weekly and monthly Relative Strength Index (RSI) show no clear signals, suggesting indecision among traders.
• Bollinger Bands: Weekly data is mildly bullish, but monthly bands indicate mild bearishness, reflecting increased volatility and downward pressure.
• Moving Averages: Daily moving averages have turned mildly bearish, signalling short-term weakness.
• KST (Know Sure Thing): Weekly KST is mildly bullish, but monthly KST is bearish, reinforcing the mixed momentum picture.
• Dow Theory: Weekly data shows no clear trend, while monthly data is mildly bullish, adding to the technical ambiguity.

Overall, the technical indicators suggest a cautious stance, with a tilt towards bearishness in the medium to long term. This shift has been pivotal in the MarketsMOJO downgrade from Sell to Strong Sell, reflecting increased risk for investors relying on technical momentum.

Market Performance Comparison: Underperformance Against Benchmarks

Makers Laboratories’ stock returns have lagged significantly behind major indices and sector benchmarks. While the Sensex has delivered a 9.81% return over the last year and a robust 256.90% over ten years, Makers Labs has posted a negative 8.08% return in the last year and a comparatively modest 109.39% over the decade.

Shorter-term returns also highlight volatility and inconsistency. The stock fell 5.13% in the past week, underperforming the Sensex’s 0.98% decline. However, it rebounded with a 10.61% gain over the last month, outperforming the Sensex’s marginal -0.14% return. This erratic performance underscores the stock’s risk profile and the challenges in timing entry points.

Shareholding and Industry Context

The company remains majority promoter-owned, which can be a double-edged sword. While promoter control can ensure strategic continuity, it may also limit external oversight and influence on governance. Within the Pharmaceuticals & Biotechnology sector, Makers Laboratories faces stiff competition from peers with stronger financial metrics and more consistent growth.

Summary and Outlook

The downgrade of Makers Laboratories Ltd to a Strong Sell rating by MarketsMOJO reflects a confluence of factors. The company’s weak long-term financial trends, including a negative operating profit CAGR and low ROE, undermine its fundamental quality. Its valuation remains expensive relative to earnings and peers, raising concerns about price sustainability.

Technically, the shift to a mildly bearish trend across multiple indicators signals caution for investors relying on momentum. The stock’s underperformance relative to major indices and sector benchmarks further diminishes its appeal.

While recent quarterly results show some operational improvements, these have not been sufficient to reverse the broader negative trends. Investors should weigh these factors carefully and consider alternative opportunities within the Pharmaceuticals & Biotechnology sector that offer stronger fundamentals and more favourable technical setups.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →